Evidence map›Paper›PMID 42125486›Full record

ArticleERJ open research2026

Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry.

Mirjam Stahl, Florian S Gerts, Sylvia Hafkemeyer, Julia Wosniok, Lutz Naehrlich, German CF Registry of the Mukoviszidose e.V. and participating sites

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mirjam StahlDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-6941-8315
Florian S GertsDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sylvia HafkemeyerMukoviszidose Institut gGmbH, Bonn, Germany.
Julia WosniokInterdisciplinary Center for Clinical Trials Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Lutz NaehrlichDepartment of Pediatrics, Justus Liebig University Giessen, Giessen, Germany.
German CF Registry of the Mukoviszidose e.V. and participating sites

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) triple therapy has been introduced as causal therapy for people with cystic fibrosis (pwCF) carrying at least one Methods: In this observational cohort study, data from the German CF Registry for pwCF who received off-label ETI for up to 365 days were used to study effects on lung function, nutritional status and sweat chloride concentration (SCC). Results: 616 pwCF (mean±sd age 28.8±13.9 years) were registered with ETI treatment within compassionate use (n=509; at least one Conclusions: Real-world data align with the results of randomised clinical trials for pwCF carrying at least one

Identifiers

PMID42125486
PMCPMC13159003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.